Adjuvant Bevacizumab Feasible for Nasopharyngeal Cancer

Adjuvant treatment is not associated with grade 3 to 4 hemorrhages or grade 5 adverse events

FRIDAY, Dec. 16 (HealthDay News) -- For patients with stage IIB to IVB locoregionally advanced nasopharyngeal carcinoma, the addition of bevacizumab to standard chemoradiation therapy is safe and effective, according to a study published online Dec. 16 in The Lancet Oncology.

Nancy Y. Lee, M.D., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues examined the feasibility and safety of adding bevacizumab to standard chemoradiotherapy for 44 patients with stage IIB to IVB locoregionally-advanced nasopharyngeal carcinoma. Patients, aged 18 years and older, were enrolled from Dec. 13, 2006, to Feb. 5, 2009. They were treated with bevacizumab in addition to the standard chemoradiation therapy. The occurrence of treatment-related grade 4 hemorrhage or any grade 5 adverse event during the first year was the primary end point.

The investigators recorded no cases of grade 3 to 4 hemorrhages or grade 5 adverse events. Treatment-related grade 1 to 2 hemorrhages were identified in nine patients. One or more grade 4 blood or bone marrow-related complications were observed in nine patients. Other grade 4 adverse events were reported, including: infections related to grade 3 to 4 neutrophil suppression (one patient with two infections); pharyngolaryngeal pain (two patients); and tinnitus, thrombosis, and radiation mucositis (one patient each). The estimated two-year locoregional progression-free interval, distant metastasis-free interval, progression-free survival, and overall survival were 83.7, 90.8, 74.7, and 90.9 percent, respectively, after a median follow-up of 2.5 years.

"The addition of bevacizumab to standard chemoradiation treatment for patients with nasopharyngeal carcinoma is feasible," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Blunt Chest Trauma
Journal of Trauma Nursing, November/December 2014
Expires: 12/31/2016 CE:2 $21.95


The School Age Child with Congenital Heart Disease
MCN, The American Journal of Maternal/Child Nursing, January/February 2015
Expires: 2/28/2017 CE:2.5 $24.95


Understanding multiple myeloma
Nursing Made Incredibly Easy!, January/February 2015
Expires: 2/28/2017 CE:2 $21.95


More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles

Comprehensive Care: Looking Beyond the Presenting Problem
Journal of Christian Nursing, January/March 2015
Free access will expire on March 2, 2015.


Pain and Alzheimer dementia: A largely unrecognized problem
Nursing Made Incredibly Easy!, January/February 2015
Free access will expire on February 16, 2015.


Glycemic control in hospitalized patients
Nursing2015 Critical Care, January 2015
Free access will expire on February 16, 2015.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events